“The combined ease of use and efficacy of Fibrocaps have the potential to constitute an important advance in surgical homeostasis,” said Dr. Renkens in the news release. “Furthermore, the spray device could become an important tool to use in surgery and to apply Fibrocaps.”
The Medicines Company expects to release the results of the trial, which included 65 sites across the Untied States and Europe to support regulatory clearance. Fibrocaps is part of the company’s ProFibrix, which also developed a complementary dry powder spray device for accurate application.
More Articles on Spine Surgery:
8 Tips for Conflict Management at Spine Practices
The Growing Trend of Lateral Spine Surgery: Q&A With Dr. Scott Spann of Pantheon Spinal
10 of the Top Mobile Apps for Spine Surgeons
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
